Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings

Tommaso Schirinzi, Paola Imbriani, Alessio D'Elia, Giulia Di Lazzaro, Nicola Biagio Mercuri, Antonio Pisani

Research output: Contribution to journalArticle

Abstract

Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.

Original languageEnglish
Pages (from-to)63-65
Number of pages3
JournalClinical Neurology and Neurosurgery
Volume156
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Sialorrhea
Parkinson Disease
Dopamine Agonists
Nonparametric Statistics
N 0437
Therapeutics

Keywords

  • Deglutition and deglutition disorders
  • Drooling
  • Non motor symptoms
  • Parkinson's Disease
  • Rotigotine
  • Sialorrhea

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Rotigotine may control drooling in patients with Parkinson's Disease : Preliminary findings. / Schirinzi, Tommaso; Imbriani, Paola; D'Elia, Alessio; Di Lazzaro, Giulia; Mercuri, Nicola Biagio; Pisani, Antonio.

In: Clinical Neurology and Neurosurgery, Vol. 156, 01.05.2017, p. 63-65.

Research output: Contribution to journalArticle

@article{4321dab404764b3da2fc15980e37b07d,
title = "Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings",
abstract = "Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.",
keywords = "Deglutition and deglutition disorders, Drooling, Non motor symptoms, Parkinson's Disease, Rotigotine, Sialorrhea",
author = "Tommaso Schirinzi and Paola Imbriani and Alessio D'Elia and {Di Lazzaro}, Giulia and Mercuri, {Nicola Biagio} and Antonio Pisani",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.clineuro.2017.03.012",
language = "English",
volume = "156",
pages = "63--65",
journal = "Clinical Neurology and Neurosurgery",
issn = "0303-8467",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rotigotine may control drooling in patients with Parkinson's Disease

T2 - Preliminary findings

AU - Schirinzi, Tommaso

AU - Imbriani, Paola

AU - D'Elia, Alessio

AU - Di Lazzaro, Giulia

AU - Mercuri, Nicola Biagio

AU - Pisani, Antonio

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.

AB - Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.

KW - Deglutition and deglutition disorders

KW - Drooling

KW - Non motor symptoms

KW - Parkinson's Disease

KW - Rotigotine

KW - Sialorrhea

UR - http://www.scopus.com/inward/record.url?scp=85015872736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015872736&partnerID=8YFLogxK

U2 - 10.1016/j.clineuro.2017.03.012

DO - 10.1016/j.clineuro.2017.03.012

M3 - Article

AN - SCOPUS:85015872736

VL - 156

SP - 63

EP - 65

JO - Clinical Neurology and Neurosurgery

JF - Clinical Neurology and Neurosurgery

SN - 0303-8467

ER -